💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mesalamine

CHEMBL704 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
153.1 g/mol
LogP
1.3
Phase
4

An anti-inflammatory drug used to treat and maintain remission of ulcerative colitis and other inflammatory bowel conditions affecting the lining of the colon. It works locally in the gut to reduce inflammation and relieve symptoms such as diarrhea, rectal bleeding, and abdominal pain.

分子量

153.1400 g/mol

LogP

1.30

TPSA

83.60 Ų

リピンスキーの五則

適合

治療領域

Cardiovascular Disease Age-Related Macular Degeneration Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Melanoma Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Deep Vein Thrombosis / Pulmonary Embolism Tuberculosis Colorectal Cancer

作用機序

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Nc1ccc(O)c(C(=O)O)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

                

                

                

                    
                    

                        
Molecular Formula

                        
C7H7NO3

                    

                    
                    

                        
HBD / HBA

                        
3 / 4

                    

                    
                    

                        
回転可能結合数

                        
1

                    

                    
                    
                    

                        
重原子数

                        
11

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
An anti-inflammatory drug used to treat and maintain remission of ulcerative colitis and other inflammatory bowel conditions affecting the lining of the colon. It works locally in the gut to reduce inflammation and relieve symptoms such as diarrhea, rectal bleeding, and abdominal pain.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mesalamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL704.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4075.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.